Lexeo Therapeutics, Inc. Common Stock

    Jurisdiction
    United States
    ISIN
    US52886X1072 (LXEO)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9

    Profile

    Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€106.46M
    EBIT margin
    0.0%
    Net income
    -€98.48M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€96.56M -2.0%
    €24.50M -€92.68M -4.0%
    €127.39M +420.0% -€70.04M -24.4%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Adler Eric Chief Medical Officer -608 $4.67 -$2.84K
    Otero Jose Manuel Chief Technical Officer -2.8K $4.67 -$13.30K
    Robertson Jenny Chief Legal Officer -542 $4.67 -$2.53K
    See Tai Sandi Chief Development Officer -382 $4.67 -$1.78K
    Townsend Richard Nolan Chief Executive Officer -2.7K $4.67 -$12.77K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 20K $70.44K +5.7K Buy

    Add to watchlist

    Notifications